Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 14/20 | 0.65 |
| ▸ | HKDC1 | Q2TB90 | 8/20 | 0.64 |
| ▸ | POLB | P06746 | 6/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.64 |
| ▸ | TDP2 | O95551 | 5/20 | 0.64 |
| ▸ | G6PD | P11413 | 5/20 | 0.64 |
| ▸ | BLM | P54132 | 5/20 | 0.64 |
| ▸ | CFTR | P13569 | 5/20 | 0.64 |
| ▸ | GOPC | Q9HD26 | 5/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.64 |
| ▸ | GALK1 | P51570 | 1/20 | 0.64 |
| ▸ | VCP | P55072 | 1/20 | 0.64 |
| ▸ | HK1 | P19367 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | KEAP1 | Q14145 | 6/20 | 0.62 |
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2243189 | 0.89 | MCL1 (0.74) | MCL1HKDC1POLBKMT2ATDP2 | |
| SCHEMBL2240877 | 0.88 | MCL1 (0.76) | MCL1HKDC1POLBKMT2ATDP2 | |
| SCHEMBL2244161 | 0.79 | MCL1 (0.75) | MCL1HKDC1POLBKMT2ATDP2 | |
| SCHEMBL14842456 | 0.79 | MCL1 (1.00) | MCL1HKDC1POLBKMT2ATDP2 | |
| SCHEMBL14851484 | 0.78 | MCL1 (1.00) | MCL1HKDC1POLBKMT2ATDP2 | |
| SCHEMBL29400973 | 0.77 | HKDC1 (1.00) | MCL1HKDC1POLBKMT2ATDP2 | |
| SCHEMBL14851297 | 0.77 | MCL1 (1.00) | MCL1HKDC1POLBKMT2ATDP2 | |
| SCHEMBL13509709 | 0.77 | STAT3 (0.62) | MCL1HKDC1POLBKMT2ATDP2 | |
| SCHEMBL14851527 | 0.77 | MEN1 (1.00) | MCL1HKDC1POLBKMT2ATDP2 | |
| SCHEMBL17211721 | 0.76 | MCL1 (0.82) | MCL1HKDC1POLBKMT2ATDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466157-B2 | Proteasome inhibitors having chymotrypsin-like activity | UNIVERSITY OF SOUTH FLORIDA (US) | 2013-06-18 | — | — | US | claimed |
| US-20120142917-A1 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2012-06-07 | — | — | US | claimed |
| WO-2010102286-A2 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-09-10 | — | — | WO | claimed |
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-8466157-B2 | Proteasome inhibitors having chymotrypsin-like activity | UNIVERSITY OF SOUTH FLORIDA (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466157-B2 | Proteasome inhibitors having chymotrypsin-like activity | UNIVERSITY OF SOUTH FLORIDA (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120142917-A1 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142917-A1 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| WO-2010102286-A2 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010005534-A2 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | PSMB7, PSMD7, PSMB6 | MCL1 62/4885HKDC1 3823/4885POLB 1693/4885 |
| US-20120142917-A1 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | PSMB4, PSME4, PSMB1 | MCL1 751/4885HKDC1 4516/4885POLB 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.